| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kristoffer Niss, Magnus E Jakobsson, David Westergaard, Kirstine G Belling, Jesper V Olsen, Søren Bruna. Effects of active farnesoid X receptor on GLUTag enteroendocrine L cells. Molecular and cellular endocrinology. vol 517. 2021-07-05. PMID:32702472. |
preventing fxr activation could boost glp-1 production and insulin secretion. |
2021-07-05 |
2023-08-13 |
Not clear |
| Retracted: Salidroside from Rhodiola wallichiana var. cholaensis reverses insulin resistance and stimulates the GLP-1 secretion by alleviating ROS-mediated activation of MAPKs signaling pathway and mitigating apoptosis. Journal of food biochemistry. 2021-07-05. PMID:34165188. |
cholaensis reverses insulin resistance and stimulates the glp-1 secretion by alleviating ros-mediated activation of mapks signaling pathway and mitigating apoptosis. |
2021-07-05 |
2023-08-13 |
Not clear |
| Kathleen G Mountjo. ELISA versus LUMINEX assay for measuring mouse metabolic hormones and cytokines: sharing the lessons I have learned. Journal of immunoassay & immunochemistry. vol 42. issue 2. 2021-07-02. PMID:33111625. |
i provide direct comparisons between luminex assay and elisa for quantitation of mouse leptin and insulin, and evaluate glucagon, glp-1, il-6, and tnfα data obtained using the 6-plex luminex assay for a high-fat diet-induced obesity study. |
2021-07-02 |
2023-08-13 |
mouse |
| Morten Hindsø, Maria S Svane, Nora Hedbäck, Jens J Holst, Sten Madsbad, Kirstine N Bojsen-Mølle. The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. vol 17. issue 7. 2021-07-01. PMID:33771461. |
a weight loss-independent augmentation of postprandial insulin secretion contributes to the improvement in glycemic control after rygb and is associated with a ∼10-fold increase in plasma concentrations of the incretin hormone glucagon-like peptide-1 (glp-1). |
2021-07-01 |
2023-08-13 |
human |
| Fernando Gomez-Peralta, Ebaa Al-Ozairi, Edward B Jude, Xiaoying Li, Julio Rosenstoc. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, obesity & metabolism. vol 23. issue 7. 2021-06-30. PMID:33651460. |
given the progressive nature of t2d, many individuals not controlled with oral therapy will require advancement to injectable therapy using either a glucagon-like peptide-1 receptor agonist (glp-1 ra), recently recommended as a first option, or traditionally a basal insulin. |
2021-06-30 |
2023-08-13 |
Not clear |
| Fernando Gomez-Peralta, Ebaa Al-Ozairi, Edward B Jude, Xiaoying Li, Julio Rosenstoc. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, obesity & metabolism. vol 23. issue 7. 2021-06-30. PMID:33651460. |
fixed-ratio combinations (frcs) of basal insulin and glp-1 ras provide a novel alternative to premix insulin for therapy intensification. |
2021-06-30 |
2023-08-13 |
Not clear |
| Fernando Gomez-Peralta, Ebaa Al-Ozairi, Edward B Jude, Xiaoying Li, Julio Rosenstoc. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, obesity & metabolism. vol 23. issue 7. 2021-06-30. PMID:33651460. |
a head-to-head trial of t2d treatment intensification with premix insulin and a frc of basal insulin plus a glp-1 ra is currently in progress, which should help to clarify the outcomes for each treatment option. |
2021-06-30 |
2023-08-13 |
Not clear |
| Fernando Gomez-Peralta, Ebaa Al-Ozairi, Edward B Jude, Xiaoying Li, Julio Rosenstoc. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, obesity & metabolism. vol 23. issue 7. 2021-06-30. PMID:33651460. |
this review discusses the unmet needs of people with t2d treated with premix insulin and provides evidence supporting frcs of basal insulin and glp-1 ras as an alternative treatment option. |
2021-06-30 |
2023-08-13 |
Not clear |
| C Di Loreto, R Celleno, L Piastrella, P Del Sindac. IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience. European review for medical and pharmacological sciences. vol 24. issue 20. 2021-06-29. PMID:33155225. |
an improvement of type 2 diabetes treatment is represented by the recent availability of a fixed-ratio combination of slow insulin degludec and glp-1 ra liraglutide (ideglira), which shows encouraging clinical trial results. |
2021-06-29 |
2023-08-13 |
Not clear |
| Rune E Kuhre, Carolyn F Deacon, Jens J Holst, Natalia Peterse. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell? Frontiers in endocrinology. vol 12. 2021-06-26. PMID:34168620. |
the beneficial actions of glp-1 go far beyond insulin secretion and appetite, and include cardiovascular benefits and possibly also beneficial effects in neurodegenerative diseases. |
2021-06-26 |
2023-08-13 |
Not clear |
| Hongjun Deng, Fengying Yang, Xiaoyi Ma, Ying Wang, Qi Chen, Li Yua. Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice. Cell transplantation. vol 29. 2021-06-25. PMID:32584149. |
the primitive bud was characterized by scattered single monohormonal cells expressing insulin, glp-1, somatostatin, or pancreatic polypeptide, and four-hormonal cells, but no acinar cells and ductal epithelial cells. |
2021-06-25 |
2023-08-13 |
mouse |
| Julio Rosenstock, Francisco Javier Ampudia-Blasco, Robert Lubwama, Xuejun Victor Peng, Anders Boss, Lizheng Shi, Vivian Fonsec. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists. Diabetes, obesity & metabolism. vol 22. issue 12. 2021-06-24. PMID:32729183. |
to assess the impact of the timing of initiating both basal insulin and glucagon-like peptide-1 receptor agonists (glp-1 ras) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (t2d) uncontrolled on oral antihyperglycaemic drugs with an hba1c of 9% or higher. |
2021-06-24 |
2023-08-13 |
Not clear |
| Nga N Nguyen, Irina Kolobova, Bruce M Wolfe, Jonathan Q Purnel. Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY Diabetes, obesity & metabolism. vol 22. issue 12. 2021-06-24. PMID:32869451. |
on the final day, glucose, insulin, glp-1, pyy |
2021-06-24 |
2023-08-13 |
human |
| Yasuo Terauchi, Daisuke Yabe, Hideaki Kaneto, Atsushi Amano, Mike Baxter, Daisuke Watanabe, Hirotaka Watada, Nobuya Inagak. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. Diabetes, obesity & metabolism. vol 22 Suppl 4. 2021-06-24. PMID:33404200. |
to explore the impact of baseline characteristics on clinical outcomes in the phase 3 lixilan jp trials which evaluated the efficacy and safety of iglarlixi, a titratable fixed-ratio combination of insulin glargine 100 units/ml (iglar) and glp-1 ra lixisenatide (lixi), vs lixi (jp-o1, nct02749890) or iglar (lixilan jp-o2, nct02752828; jp-l, nct02752412) in japanese people with type 2 diabetes uncontrolled on oral antidiabetes drugs (oads; jp-o1, jp-o2) or oads and basal insulin (jp-l). |
2021-06-24 |
2023-08-13 |
Not clear |
| Bhumi M Shah, Palmi Modi, Priti Trived. Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors. Current medicinal chemistry. vol 28. issue 18. 2021-06-22. PMID:33045957. |
two major incretin hormones like glucose-dependent insulinotropic polypeptide (gip) and glucagonlike peptide - 1 (glp-1) stimulate insulin release after a meal, but their action is inhibited by enzyme dipeptidyl peptidase- iv. |
2021-06-22 |
2023-08-13 |
Not clear |
| Caroline Tsao, Peng Zhang, Zhefan Yuan, Dianyu Dong, Kan Wu, Liqian Niu, Patrick McMullen, Sijin Luozhong, Hsiang-Chieh Hung, Yu-Hong Cheng, Shaoyi Jian. Zwitterionic Polymer Conjugated Glucagon-like Peptide-1 for Prolonged Glycemic Control. Bioconjugate chemistry. vol 31. issue 7. 2021-06-21. PMID:32510929. |
glucagon-like peptide-1 (glp-1) is of particular interest for treating type 2 diabetes mellitus (t2dm), as it induces insulin secretion in a glucose-dependent fashion and has the potential to facilitate weight control. |
2021-06-21 |
2023-08-13 |
mouse |
| Zhiyu Zhang, Xiaorong Yu, Xin Gen. Protective role of three differently processed corn bran on glucose and lipid concentrations in d-galactose-induced mice model. Journal of food biochemistry. vol 44. issue 8. 2021-06-21. PMID:32557758. |
mice were submitted under oral glucose tolerance test (ogtt).then, the serum insulin, glucagon-like peptide-1(glp-1), serum c-peptide, hepatic glycogen (hg), muscle glycogen (mg), total cholesterol (tc), triglyceride (tg), low-density lipoprotein cholesterol (ldl-c), high-density lipoprotein cholesterol (hdl-c) of all the mice were detected. |
2021-06-21 |
2023-08-13 |
mouse |
| Cyrus Desouza, Andreas R Kirk, Kamal K Mangla, Michael L Wolden, Ildiko Lingva. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). BMJ open diabetes research & care. vol 8. issue 2. 2021-06-21. PMID:33376084. |
real-world clinical outcomes following treatment intensification with glp-1 ra, oads or insulin in patients with type 2 diabetes on two oral agents (pathway 2-oads). |
2021-06-21 |
2023-08-13 |
Not clear |
| Cyrus Desouza, Andreas R Kirk, Kamal K Mangla, Michael L Wolden, Ildiko Lingva. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). BMJ open diabetes research & care. vol 8. issue 2. 2021-06-21. PMID:33376084. |
in this retrospective, observational study, we compared intensification with a glucagon-like peptide-1 receptor agonist (glp-1 ra), oral antidiabetic drugs (oads), and insulin in patients receiving two oads, using us electronic health records and claims data. |
2021-06-21 |
2023-08-13 |
Not clear |
| Elin Manell, Emmi Puuvuori, Anna Svensson, Irina Velikyan, Gry Hulsart-Billström, Patricia Hedenqvist, Jens Juul Holst, Marianne Jensen Waern, Olof Eriksso. Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography. BMJ open diabetes research & care. vol 9. issue 1. 2021-06-21. PMID:33903116. |
glucagon-like peptide-1 (glp-1) increases insulin secretion from pancreatic beta-cells and glp-1 receptor (glp-1r) agonists are widely used as treatment for type 2 diabetes mellitus. |
2021-06-21 |
2023-08-13 |
Not clear |